Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.
Valle, Juan W
AffiliationIRCCS Foundation, National Institute of Tumors, Milan, Italy
MetadataShow full item record
AbstractRecently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; P<0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity.
CitationImpact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. 2017, 10:5013-5030 Onco Targets Ther
JournalOncoTargets and Therapy